Trials / Not Yet Recruiting
Not Yet RecruitingNCT07512583
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
Phase Ib/II Clinical Trial of TQB2930 Injection in Combination With TQB2102 for Injection in Patients With HER2-Expressing Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 178 (estimated)
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, multi-cohort phase Ib/II clinical study to evaluate the efficacy and safety of TQB2930 in combination with TQB2102 in patients with HER2-expressing advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TQB2930 injection+TQB2102 for injection | TQB2930 Injection is a Human Epidermal Growth Factor Receptor 2 (HER2) bispecific antibody. TQB2102 for injection is a HER2 - targeted dual epitope Antibody-Drug Conjugate (ADC). |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2028-03-01
- Completion
- 2028-12-01
- First posted
- 2026-04-06
- Last updated
- 2026-04-06
Source: ClinicalTrials.gov record NCT07512583. Inclusion in this directory is not an endorsement.